Related Experiment Videos
Angiotensin-converting enzyme inhibitors in congestive heart failure
1Cardiology Section, Veterans Administration Medical Center, Fresno, Calif 93703.
Insights
Angiotensin-converting enzyme inhibitors significantly improve congestive heart failure (CHF) outcomes. These drugs enhance hemodynamics and quality of life, offering survival benefits and managing ventricular remodeling post-myocardial infarction.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Angiotensin-converting enzyme (ACE) inhibitors have revolutionized congestive heart failure (CHF) management.
- Initial use in severe CHF expanded to mild to moderate cases due to demonstrated benefits.
Purpose of the Study:
- To review the impact of ACE inhibitors on CHF treatment.
- To compare different ACE inhibitors regarding efficacy and side effect profiles.
Main Methods:
- Literature review of clinical trials and studies on ACE inhibitors in CHF.
- Analysis of pharmacokinetic and pharmacodynamic data.
Main Results:
- ACE inhibitors provide acute and sustained improvements in ventricular hemodynamics and quality of life.
- Captopril plus diuretics is a viable alternative to digoxin in mild to moderate CHF.
- Enalapril and lisinopril show efficacy in moderate to severe CHF when combined with standard therapies.
- ACE inhibitors, specifically captopril and enalapril, improve survival and attenuate left ventricular dilatation post-myocardial infarction.
- Pharmacokinetic differences influence clinical use, with longer-acting agents potentially causing prolonged hypotension.
Conclusions:
- ACE inhibitors are crucial for managing CHF across severity spectrums.
- Individual agent selection should consider pharmacokinetic profiles to optimize patient outcomes and minimize adverse effects like hypotension.
Abstract:
Angiotensin-converting enzyme inhibitors have had a significant impact on the treatment of congestive heart failure (CHF). Hemodynamic and clinical improvements in patients with severe CHF fostered the use of angiotensin-converting enzyme inhibitors in mild to moderate CHF. Angiotensin-converting enzyme inhibitors produce acute and sustained improvements in ventricular hemodynamics and quality of life. Captopril plus diuretic therapy is an effective alternative to digoxin in patients with mild to moderate CHF. Enalapril maleate and lisinopril have been shown to be effective in moderate to severe CHF when combined with digoxin and diuretics. Captopril and enalapril also improve survival in selected patients; captopril attenuates left ventricular dilatation after myocardial infarction. Although all angiotensin-converting enzyme inhibitors are similar in mechanism of action, pharmacokinetic differences impact their clinical use. Prolonged symptomatic hypotension compromising systemic perfusion and organ function has been reported with longer-acting agents; hypotension is usually short-lived and rarely compromises organ function with shorter-acting agents.